The FDA has approved a first-in-class bladder cancer drug. Anktiva (interleukin (IL)-15 superagonist nogapendekin alfa inbakicept-pmln) administered with bacillus Calmette-Guérin was approved for ...
Hercessi marks Accord BioPharma’s first biosimilar to be approved in the United States, with multiple indications for ...
Autoimmune Disorders: Bristol Myers Squibb has entered into a research agreement with Repertoire to develop vaccines for ...
A California-based immunotherapy company with local operations received good news this week that the U.S. Food and Drug Administration has approved its bladder cancer treatment drug. ImmunityBio ...
Lumicell developed the technology to enable physicians to detect residual cancer in the breast cavity after surgery.
The Food and Drug Administration approved Tivdak for metastatic cervical cancer that progressed on or after chemotherapy. The Food and Drug Administration (FDA) approved Tivdak (tisotumab vedotin-tftv ...
The U.S. Food and Drug Administration (FDA ... available for BCG-unresponsive non–muscle-invasive bladder cancer. "The FDA approval of N-803 heralds a new era in the management of BCG ...
A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer. The Food and Drug Administration (FDA) has ...
The Food and Drug Administration approved ... surgeons to detect residual cancer in the breast cavity after performing a lumpectomy to remove the tumor. An FDA advisory committee voted in March ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results